First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Helland, Øystein ^a,b   Popa, Mihaela ^c   Vintermyr, Olav K ^a,b   Molven, Anders ^a,b   Gjertsen, Bjørn Tore ^a,b   Bjørge, Line ^a,b   McCormack, Emmet ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c KinN Therapeutics   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DNA; LUCIFERASE; MICROSATELLITE DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; HUMAN CELL; HYSTERECTOMY; IMMUNE DEFICIENCY; METASTASIS RESECTION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CARCINOMA; PERITONEUM METASTASIS; QUANTITATIVE ANALYSIS; SALPINGOOOPHORECTOMY; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CYSTADENOCARCINOMA, SEROUS; DISEASE COURSE; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; LUMINESCENCE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICROSATELLITE REPEATS; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897052086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089527     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Mutch DG (2002) Surgical management of ovarian cancer. Semin Oncol 29: 3-8.
3. Zivanovic O, Aldini A, Carlson JW, Chi DS (2009) Advanced cytoreductive surgery: American perspective. Gynecol Oncol 114: S3-9.
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200. (Pubitemid 46606249)
5. du Bois A, Neijt JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 10 Suppl 1: 35-41.
6. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516. (Pubitemid 37328838)
7. Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2: S134-139.
8. Connolly DC (2009) Animal models of ovarian cancer. Cancer Treat Res 149: 353-391.
9. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9: 4227-4239. (Pubitemid 37204044)
10. Ricci F, Broggini M, Damia G (2013) Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. Cancer Treat Rev 39: 561-568.
11. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, et al. (2005) HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 12: 789-802. (Pubitemid 41614474)
12. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, et al. (2012) Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol 30: e45-48.
13. Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40: 852-857.
14. Teicher BA (2006) Tumor models for efficacy determination. Mol Cancer Ther 5: 2435-2443.
15. Cordero AB, Kwon Y, Hua X, Godwin AK (2010) In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp.
16. Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE, et al. (2011) Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia 13: 1152-1161.
17. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR (2011) Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 17: 7359-7372.
18. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ, Jr., et al. (2011) Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One 6: e24420.
19. Schorge JO, McCann C, Del Carmen MG (2010) Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol 3: 111-117.
20. Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, et al. (2012) Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer 107: 360-369.
21. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, et al. (2005) Ascitic complement system in ovarian cancer. Br J Cancer 92: 895-905. (Pubitemid 40462637)
22. Lorens JB, Jang Y, Rossi AB, Payan DG, Bogenberger JM (2000) Optimization of regulated LTR-mediated expression. Virology 272: 7-15. (Pubitemid 30429425)
23. Ke XS, Li WC, Hovland R, Qu Y, Liu RH, et al. (2011) Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res 317: 234-247.
24. FIGO Committee on Gynecologic Oncology (2009) Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 105: 3-4.
25. Nadeau ME, Kaartinen MJ, Lague MN, Paquet M, Huneault LM, et al. (2009) A mouse surgical model for metastatic ovarian granulosa cell tumor. Comp Med 59: 553-556.
26. Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, et al. (2013) Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol 208: 501.e501-e507.
27. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, et al. (2012) Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 26: 910-917.
28. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, et al. (2011) Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A 108: 6468-6473.
29. Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101-104.
30. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413-420. (Pubitemid 13158699)
31. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, et al. (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106: 69-74. (Pubitemid 46898573)
32. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042. (Pubitemid 39625247)
33. Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, et al. (1998) A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis 16: 751-756. (Pubitemid 29170485)
34. Fu X, Hoffman RM (1993) Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13: 283-286. (Pubitemid 23196757)
35. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224. (Pubitemid 40170640)
36. Czernobilsky B, Moll R, Levy R, Franke WW (1985) Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol 37: 175-190. (Pubitemid 15054927)
37. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, et al. (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17: 1514-1520.
38. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126.
39. Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, et al. (2013) Sonoporation-Enhanced Chemotherapy Significantly Reduces Primary Tumour Burden in an Orthotopic Pancreatic Cancer Xenograft. Mol Imaging Biol.
40. Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, et al. (2013) In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme. Mol Imaging 12: 161-172.
41. Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, et al. (2011) A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol 37: 189-205.
42. Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71: 517-523.
43. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259. (Pubitemid 34177431)
44. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708. (Pubitemid 30365530)
45. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, et al. (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 17: 1315-1319.
46. Harlaar NJ, Kelder W, Sarantopoulos A, Bart J, Themelis G, et al. (2013) Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an alpha(v)beta(3-)integrin targeted agent. Gynecol Oncol 128: 590-595.
47. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, et al. (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52: 1778-1785.
48. Vidal A, Munoz C, Guillen MJ, Moreto J, Puertas S, et al. (2012) Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 18: 5399-5411.